Friday 16 October 2026
Export ZNTL’s income statement to Excel — free account
Zentalis Pharmaceuticals, Inc.
ZNTL Healthcare Biotechnology
Zentalis Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $67.4 million. In the quarter to June 2026, EPS fell 59.5% and free cash flow fell 9.06%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.13
0.11
−4.91%
Follow ZNTL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(49.18%) | (49.53%) | (51.93%) | (66.75%) | |
| (38.39%) | (38.11%) | (38.97%) | (49.22%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(58.77%) | (62.47%) | (66.91%) | (95.48%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(1.85) | (1.73) | (1.78) | (1.79) | |
Free Cash Flow |
(133.44) | (124.55) | (124.91) | (128.00) | |
Capital Expenditures |
0.57 | 0.70 | 0.66 | 0.10 | |
| Other line items | |||||
Cash ROIC |
(25.01%) | (26.95%) | (31.67%) | (40.22%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.90 | 0.91 | 1.01 | 0.92 | |
Depreciation/Fixed assets |
0.31 | (0.73) | (0.50) | (0.24) | |
Capex/Depreciation |
0.63 | (0.34) | (0.50) | (0.16) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.86) | (1.74) | (1.79) | (1.80) | |
Capex per Share |
0.01 | 0.01 | 0.01 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates